<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Profound Medical Corp — News on 6ix</title>
<link>https://6ix.com/company/profound-medical-corp</link>
<description>Latest news and press releases for Profound Medical Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 12:37:49 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/profound-medical-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835fb8078dffbe2df131caf.webp</url>
<title>Profound Medical Corp</title>
<link>https://6ix.com/company/profound-medical-corp</link>
</image>
<item>
<title>Profound Medical to Release First Quarter 2026 Financial Results on May 7 - Conference Call to Follow</title>
<link>https://6ix.com/company/profound-medical-corp/news/profound-medical-to-release-first-quarter-2026-financial-results-on-may-7-conference-call-to-follow</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/profound-medical-to-release-first-quarter-2026-financial-results-on-may-7-conference-call-to-follow</guid>
<pubDate>Thu, 16 Apr 2026 12:37:49 GMT</pubDate>
<description>TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (&#x2...</description>
</item>
<item>
<title>Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference</title>
<link>https://6ix.com/company/profound-medical-corp/news/profound-medical-to-participate-in-the-2026-bloom-burton-and-co-healthcare-investor-conference</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/profound-medical-to-participate-in-the-2026-bloom-burton-and-co-healthcare-investor-conference</guid>
<pubDate>Tue, 14 Apr 2026 11:30:00 GMT</pubDate>
<description>TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (&#x2...</description>
</item>
<item>
<title>Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO&#xAE; to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting</title>
<link>https://6ix.com/company/profound-medical-corp/news/incision-free-mri-guided-prostate-treatment-with-profounds-tulsa-proandxae-to-be-featured-in-multiple-presentations-at-the-upcoming-2026-society-of-interventional-radiology-scientific-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/incision-free-mri-guided-prostate-treatment-with-profounds-tulsa-proandxae-to-be-featured-in-multiple-presentations-at-the-upcoming-2026-society-of-interventional-radiology-scientific-meeting</guid>
<pubDate>Wed, 01 Apr 2026 12:15:00 GMT</pubDate>
<description>TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (&#x2...</description>
</item>
<item>
<title>Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure(TM) Milestone</title>
<link>https://6ix.com/company/profound-medical-corp/news/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-proceduretm-milestone</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/profound-medical-congratulates-texas-prostate-on-achieving-100th-tulsa-proceduretm-milestone</guid>
<pubDate>Fri, 27 Mar 2026 11:45:00 GMT</pubDate>
<description>TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (&#x2...</description>
</item>
<item>
<title>Upcoming Meeting Dates - March 23, 2026</title>
<link>https://6ix.com/company/profound-medical-corp/news/upcoming-meeting-dates-march-23-2026-17</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/upcoming-meeting-dates-march-23-2026-17</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Toronto, Ontario--(Newsfile Corp. - March 23, 2026) - The following is a list of Upcoming Meeting...</description>
</item>
<item>
<title>CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence</title>
<link>https://6ix.com/company/profound-medical-corp/news/captain-trial-comparing-profounds-mri-guided-tulsa-proceduretm-to-robotic-radical-prostatectomy-successfully-meets-primary-safety-endpoint-preservation-of-erectile-function-and-urinary-continence</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/captain-trial-comparing-profounds-mri-guided-tulsa-proceduretm-to-robotic-radical-prostatectomy-successfully-meets-primary-safety-endpoint-preservation-of-erectile-function-and-urinary-continence</guid>
<pubDate>Fri, 13 Mar 2026 14:30:00 GMT</pubDate>
<description>– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA treatment demonstrates a meaningful and statistically significant improvement over robotic RP in the preservation of erectile function together with continence at 6 months – TORONTO, March 13, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial</description>
</item>
<item>
<title>CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure(TM) to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence</title>
<link>https://6ix.com/company/profound-medical-corp/news/captain-trial-comparing-profounds-mri-guided-tulsa-proceduretm-to-robotic-radical-prostatectomy-successfully-meets-primary-safety-endpoint-preservation-of-erectile-function-and-urinary-continence-489</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/captain-trial-comparing-profounds-mri-guided-tulsa-proceduretm-to-robotic-radical-prostatectomy-successfully-meets-primary-safety-endpoint-preservation-of-erectile-function-and-urinary-continence-489</guid>
<pubDate>Fri, 13 Mar 2026 14:30:00 GMT</pubDate>
<description>&#x2013; First multicenter, randomized controlled trial directly comparing a new technology to ro...</description>
</item>
<item>
<title>Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24</title>
<link>https://6ix.com/company/profound-medical-corp/news/profound-medical-to-host-investor-call-to-discuss-first-clinical-outcomes-from-the-captain-trial-on-march-13-participate-in-roth-investor-conference-on-march-22-24</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/profound-medical-to-host-investor-call-to-discuss-first-clinical-outcomes-from-the-captain-trial-on-march-13-participate-in-roth-investor-conference-on-march-22-24</guid>
<pubDate>Mon, 09 Mar 2026 12:30:00 GMT</pubDate>
<description>TORONTO, March 09, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (&#x2...</description>
</item>
<item>
<title>Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/profound-medical-corp/news/profound-medical-reports-fourth-quarter-and-full-year-2025-financial-results-66</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/profound-medical-reports-fourth-quarter-and-full-year-2025-financial-results-66</guid>
<pubDate>Thu, 05 Mar 2026 21:05:00 GMT</pubDate>
<description>TORONTO, March 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (&#x2...</description>
</item>
<item>
<title>Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow</title>
<link>https://6ix.com/company/profound-medical-corp/news/profound-medical-release-fourth-quarter-213000748</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/profound-medical-release-fourth-quarter-213000748</guid>
<pubDate>Thu, 12 Feb 2026 21:30:00 GMT</pubDate>
<description>TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, will announce its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. F</description>
</item>
<item>
<title>Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th - Conference Call to Follow</title>
<link>https://6ix.com/company/profound-medical-corp/news/profound-medical-to-release-fourth-quarter-and-full-year-2025-financial-results-on-march-5th-conference-call-to-follow</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/profound-medical-to-release-fourth-quarter-and-full-year-2025-financial-results-on-march-5th-conference-call-to-follow</guid>
<pubDate>Thu, 12 Feb 2026 21:30:00 GMT</pubDate>
<description>TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (&#x20...</description>
</item>
<item>
<title>Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease</title>
<link>https://6ix.com/company/profound-medical-corp/news/profound-medical-honored-inovait-2025-133000700</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/profound-medical-honored-inovait-2025-133000700</guid>
<pubDate>Thu, 12 Feb 2026 13:30:00 GMT</pubDate>
<description>TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is pleased to announce that it has received the 2025/2026 Mount Logan Award from INOVAIT, the Canadian national network for commercializing breakthroughs in image-guided therapy (IGT) and artificial intelligence (“AI”). “The Mount Logan Award recognizes an INOVAIT industry member who has consistently exceed</description>
</item>
<item>
<title>Profound Medical Honored with INOVAIT's 2025-2026 Mount Logan Award Recognizing the TULSA Procedure(TM) for Prostate Disease</title>
<link>https://6ix.com/company/profound-medical-corp/news/profound-medical-honored-with-inovaits-2025-2026-mount-logan-award-recognizing-the-tulsa-proceduretm-for-prostate-disease</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/profound-medical-honored-with-inovaits-2025-2026-mount-logan-award-recognizing-the-tulsa-proceduretm-for-prostate-disease</guid>
<pubDate>Thu, 12 Feb 2026 13:30:00 GMT</pubDate>
<description>TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (&#x20...</description>
</item>
<item>
<title>PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve&#xAE; Procedures, Expanding Access to Incision-Free Care for Women's Health</title>
<link>https://6ix.com/company/profound-medical-corp/news/pro-familia-and-profound-medical-celebrate-500-sonalleveandxae-procedures-expanding-access-to-incision-free-care-for-womens-health</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/pro-familia-and-profound-medical-celebrate-500-sonalleveandxae-procedures-expanding-access-to-incision-free-care-for-womens-health</guid>
<pubDate>Thu, 05 Feb 2026 13:00:00 GMT</pubDate>
<description>TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (&#x...</description>
</item>
<item>
<title>PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health</title>
<link>https://6ix.com/company/profound-medical-corp/news/pro-familia-profound-medical-celebrate-130000987</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/pro-familia-profound-medical-celebrate-130000987</guid>
<pubDate>Thu, 05 Feb 2026 13:00:00 GMT</pubDate>
<description>Milestone reflects accelerating adoption of innovative, non-surgical treatment options for uterine conditionsTORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today that PRO FAMILIA Specialist Hospital in Rzeszów, Poland has completed its 500th Sonalleve® Procedure.</description>
</item>
<item>
<title>Profound Medical Announces Upcoming Investor Events</title>
<link>https://6ix.com/company/profound-medical-corp/news/profound-medical-announces-upcoming-investor-213000988</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/profound-medical-announces-upcoming-investor-213000988</guid>
<pubDate>Tue, 27 Jan 2026 21:30:00 GMT</pubDate>
<description>TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce its participation in the following investor events in February. Lake Street Life-Sciences Invitational: Profound is scheduled to participate in a series of one-on-one meetings February 4th-5th in Scottsda</description>
</item>
<item>
<title>Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®</title>
<link>https://6ix.com/company/profound-medical-corp/news/mount-sinai-becomes-first-metro-123000063</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/mount-sinai-becomes-first-metro-123000063</guid>
<pubDate>Thu, 15 Jan 2026 12:30:00 GMT</pubDate>
<description>Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World Report® for 2025-26 TORONTO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to</description>
</item>
<item>
<title>Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO&#xAE;</title>
<link>https://6ix.com/company/profound-medical-corp/news/mount-sinai-becomes-first-in-metro-new-york-to-deliver-incision-free-mri-guided-prostate-treatment-with-tulsa-proandxae</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/mount-sinai-becomes-first-in-metro-new-york-to-deliver-incision-free-mri-guided-prostate-treatment-with-tulsa-proandxae</guid>
<pubDate>Thu, 15 Jan 2026 12:30:00 GMT</pubDate>
<description>Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and se...</description>
</item>
<item>
<title>Profound Surpasses 2025 TULSA-PRO&#xAE; Installed Base Goal</title>
<link>https://6ix.com/company/profound-medical-corp/news/profound-surpasses-2025-tulsa-proandxae-installed-base-goal</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/profound-surpasses-2025-tulsa-proandxae-installed-base-goal</guid>
<pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
<description>TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (&#x20...</description>
</item>
<item>
<title>Profound Surpasses 2025 TULSA-PRO® Installed Base Goal</title>
<link>https://6ix.com/company/profound-medical-corp/news/profound-surpasses-2025-tulsa-pro-130000634</link>
<guid isPermaLink="true">https://6ix.com/company/profound-medical-corp/news/profound-surpasses-2025-tulsa-pro-130000634</guid>
<pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
<description>Company’s year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systemsTORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that its TULSA-PRO® system installed base stood at 78 as of December 31, 2025 — higher than</description>
</item>
</channel>
</rss>